Articles from Veramorph LLC

Veramorph LLC (VeraMorph), a science-driven startup developing a novel degradable gel as a solubility-enhancing oral drug delivery technology, has been awarded a Small Business Innovation Research (SBIR) Fast Track Grant from the National Cancer Institute (NCI) of the National Institutes of Health (grant number R44CA306533). The SBIR program is a highly competitive, awards-based program designed to stimulate technological innovations developed by U.S. small businesses on a path to commercialization. This Fast Track award will accelerate the clinical translation of an oral formulation of fulvestrant for estrogen receptor positive (ER+) metastatic breast cancer (mBC), which is the company’s first oral drug product using its oral drug delivery platform. VeraMorph’s oral fulvestrant product has been well tolerated and demonstrated 55% improved tumor growth inhibition relative to the currently approved monthly intramuscular injection in preclinical studies. This grant will financially support replication of the safety and efficacy outcomes as well as IND-enabling studies of orally dosed fulvestrant, and by association VeraMorph’s drug delivery technology. This SBIR award brings the company’s total funding to roughly $5M.